Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD7-C52H4 | Cynomolgus | Cynomolgus CD117 / c-kit (D198E) Protein, His Tag (MALS verified) |  |
|
|
| CD7-H525b | Human | Human CD117 / c-kit Protein, Fc Tag (MALS verified) |  |
|
|
| CD7-C82E4 | Cynomolgus | Biotinylated Cynomolgus CD117 / c-kit Protein, His,Avitag (MALS verified) |  |
|
|
| CD7-C52H9 | Cynomolgus | Cynomolgus CD117 / c-kit Protein, His Tag (MALS verified) |  |
|
|
| CD7-H82E6 | Human | Biotinylated Human CD117 / c-kit Protein, His,Avitag (MALS verified) |  |
|
|
| CD7-R5259 | Rhesus macaque | Rhesus macaque CD117 / c-kit Protein, Fc Tag (MALS verified) |  |
|
|
| CD7-M5259 | Mouse | Mouse CD117 / c-kit Protein, Fc Tag (MALS verified) |  |
|
|
| CD7-H5255 | Human | Human CD117 / c-kit Protein, Fc Tag (MALS verified) |  |
|
|
| CD7-H52H4 | Human | Human CD117 / c-kit Protein, His Tag (MALS verified) |  |
|
|
Biotinylated Human SCF, Avitag,His Tag (Cat. No. SCF-H82E1) captured on Biotin CAP-Series S Sensor Chip can bind Human CD117, His Tag (Cat. No. CD7-H52H4) with an affinity constant of 0.236 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Thyroid Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Medullary thyroid cancer (MTC); Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
| Imatinib mesylate | CGP-57148B; CGP-57148; STI-571; QTI-571; CTI-571; VR325; AER-901; YD-312; TNX-201 | Approved | Novartis Pharma Ag | glivic, 格列卫, Gleevec, Ruvise, Glivec, Gleevec/Glivec | EU | Leukemia, Myelogenous, Chronic | Novartis Europharm Ltd | 2001-05-10 | Diabetes Mellitus, Type 1; Hypereosinophilic Syndrome; Leukemia; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Ovarian Neoplasms; Solid tumours; Hypertension, Pulmonary; Hematopoietic stem cell transplantation (HSCT); Neoplasm, Residual; Skin Melanoma; Hematologic Neoplasms; Genital Diseases, Male; Ovarian germ cell tumor; Fibrosarcoma; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Loiasis; Rhinitis, Allergic, Seasonal; Polycythemia Vera; Genital Neoplasms, Male; Abdominal Neoplasms; Leukemia, Hairy Cell; Histiocytoma, Malignant Fibrous; Desmoplastic Small Round Cell Tumor; Rectal Neoplasms; Stomach Neoplasms; Myeloproliferative Disorders; Skin Neoplasms; Leukemia, Myelomonocytic, Chronic; Coronavirus Disease 2019 (COVID-19); Scleroderma, Systemic; Graft vs Host Disease; Dermatofibrosarcoma; Liver Cirrhosis; Neoplasms; Neurofibromatoses; Mastocytosis, Systemic; Idiopathic Pulmonary Fibrosis; Myelodysplastic Syndromes; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma | Details |
| Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
| Avapritinib | BLU-285; CS-3007 | Approved | Blueprint Medicines Corp | Ayvakit, Ayvakyt, 泰吉华, Taijihua | United States | Gastrointestinal Stromal Tumors | Blueprint Medicines Corp | 2020-01-09 | Solid tumours; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Mastocytosis, Systemic; Central Nervous System Neoplasms; Leukemia, Mast-Cell; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Adenocarcinoma | Details |
| Vorolanib | CM-082; X-82; EYP-1901 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Melanoma; Carcinoma, Non-Small-Cell Lung; Diabetic Retinopathy; Macular Degeneration; Carcinoma, Hepatocellular; Choroidal Neovascularization; Adenocarcinoma; Eye Diseases; Leukemia, Myeloid, Acute; Retinal Degeneration; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms | Details |
| Ripretinib | DCC-2618 | Approved | Deciphera Pharmaceuticals | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors | Details |
| Olverembatinib | D-824; GZD-824; APG-1351; GIBH-824; HQP-1351 | Approved | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | 耐立克 | Mainland China | Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Guangzhou Shunjian Biomedical Technology Co Ltd | 2021-11-25 | Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Solid tumours; Leukemia, Myeloid; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors | Details |
| Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Common Bile Duct Neoplasms; Leukemia, Myeloid, Accelerated Phase; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Hematologic Neoplasms; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Solid tumours; Leukemia | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
| Dasatinib Hydrate | BMS-354825; XS-004; NSC-732517 | Approved | Bristol-Myers Squibb Company | Spraysel, 施达赛, Dasynoc, Spricel, Sprycel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leukemia; Liver Neoplasms; Hematologic Neoplasms; Hypereosinophilic Syndrome; Solid tumours; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Bone metastases; Skin Melanoma; Rhabdomyosarcoma; Chondrosarcoma; Immunoproliferative Small Intestinal Disease; Ovarian Neoplasms; Leukemia, Myeloid; Cystadenocarcinoma; HIV Infections; Rectal Neoplasms; Polycythemia Vera; Leukemia, Lymphoid; Leukemia, Hairy Cell; Hormone-Resistant Prostate Neoplasms; Idiopathic Pulmonary Fibrosis; Colonic Neoplasms; Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Scleroderma, Systemic; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Mastocytosis, Systemic; Leukemia-Lymphoma, Adult T-Cell; Hodgkin Disease; Carcinoma, Verrucous; Lymphoma, Large-Cell, Immunoblastic; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (C | Details |
| Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Metastatic breast cancer; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Neurofibroma, Plexiform; Neurofibrosarcoma; Giant Cell Tumors; Sarcoma; Giant Cell Tumor of Tendon Sheath; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pancreatic Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Synovitis, Pigmented Villonodular; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Solid tumours | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Osteosarcoma; Germinoma; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Uterine Cervical Diseases; Genital Neoplasms, Female; Gliosarcoma; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Lung Neoplasms; Nasopharyngeal Carcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Psoriasis; Gastrinoma; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Neoplasm Metastasis; Breast Neoplasms, Male; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Paraganglioma; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Sarcoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Choriocarcinoma; Uterine Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Glioma; Carcinoma, Embryonal; Skin Melanoma; Neoplasms; Herpes Genitalis; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Insulinoma; Pheochromo | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Rhabdomyosarcoma; Solid tumours; Ovarian Neoplasms; Fibromatosis, Aggressive; Kidney Neoplasms; Leukemia, Myeloid; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Islet Cell; Insulinoma; Vipoma; Hemangiosarcoma; Esophageal Neoplasms; Wilms Tumor; Hypertension, Portal; Thyroid Carcinoma, Anaplastic; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Lymphomatoid Granulomatosis; Carcinoma, Transitional Cell; Colonic Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Endocrine Neoplasia Type 2a; Lymphoma, Large-Cell, Immunoblastic; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, | Details |
| Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Barzolvolimab | CDX-0159 | Phase 3 Clinical | Yale University, University Of Toronto - St. George Campus | Chronic Urticaria; Prurigo Nodularis; Skin Diseases; Eosinophilic Esophagitis; Urticaria; Dermatitis, Atopic | Details |
| Seralutinib | GB-002; PK-10571 | Phase 3 Clinical | Gilead Sciences Inc | Pulmonary Arterial Hypertension | Details |
| Chiauranib | CS-2164; CS2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Carcinoma, Hepatocellular | Details |
| Bezuclastinib | PLX-9486; CGT-9486 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Hematologic Neoplasms; Mastocytosis, Systemic; Leukemia, Mast-Cell; Gastrointestinal Stromal Tumors; Neoplasm Metastasis; Mastocytosis | Details |
| oral enteric coated imatinib (Tenax Therapeutics) | TNX-201 (Tenax Therapeutics) | Phase 3 Clinical | PH Precision Med | Pulmonary Arterial Hypertension | Details |
| Sitravatinib | MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
| Elenestinib | BLU-263 | Phase 3 Clinical | Blueprint Medicines Corp | Mastocytosis, Systemic; Mastocytosis | Details |
| Autologous Human C-Kit Cardiac Stem Cells (CSCs) II (ISCI / University of Miami Miller School of Medicine) | Phase 2 Clinical | University Of Miami, Elpiscience (Shanghai) Biopharma Ltd | Myocardial Infarction; Ventricular Dysfunction, Left | Details | |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
| Briquilimab | AMG-191; JSP-191; JSP191 | Phase 2 Clinical | Amgen Inc, National Heart, Lung And Blood Institute, Stanford University | Chronic Urticaria; Myelodysplastic Syndromes; Severe Combined Immunodeficiency; Asthma; Leukemia, Myeloid, Acute; Granulomatous Disease, Chronic; Immunologic Deficiency Syndromes; Anemia, Sickle Cell | Details |
| DCC-3009 | DCC-3009 | Phase 2 Clinical | Deciphera Pharmaceuticals Inc | Gastrointestinal Stromal Tumors | Details |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| Opelkibart elmanitin | MGTA-117 | Phase 2 Clinical | Heidelberg Pharma AG | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| 18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Lymphoma; Diagnostic agents; Melanoma | Details |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
| Amorphous Formulation of Sorafenib in Mesoporous Magnesium Carbonate | DPH001; DPH-001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| THB-335 | THB-335; THB335 | Phase 1 Clinical | Third Harmonic Bio | Inflammation | Details |
| CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Fibrosis; Inflammation; Hypersensitivity | Details |
| QX-013N | QX-013-N; QX013N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Chronic Urticaria; Urticaria | Details |
| NN-2101 | NN-2101 | Phase 1 Clinical | Novelty Nobility Inc | Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
| NN-3201 | NN-3201 | Phase 1 Clinical | Novelty Nobility Inc | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Uveal melanoma; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute | Details |
| THB-001 | THB-001 | Phase 1 Clinical | Novartis Corp | Gastrointestinal Diseases; Chronic Urticaria; Respiratory Tract Diseases | Details |
| T-1301 | T-1301; DBPR-216 | Phase 1 Clinical | Taivex Therapeutics Corp | Solid tumours; Lymphoma | Details |
| GS-0174 | GS-0174 | Phase 1 Clinical | Forty Seven Inc | Hematologic Neoplasms | Details |
| TR-64 | TR-64 | Phase 1 Clinical | Tarapeutics Science Inc | Solid tumours; Gastrointestinal Stromal Tumors | Details |
| AZD-3229 | NB-003; NB003; AZD-3229; AZD3229 | Phase 1 Clinical | Astrazeneca Turkey | Solid tumours; Gastrointestinal Stromal Tumors; Influenza B virus infection | Details |
| AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
This web search service is supported by Google Inc.
A-Z
